Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need. Our extensive experience in drug discovery, combined with our unique expertise in targeted protein degradation, allows us to quickly develop an extensive compound library of novel and drug-like structures which generates high-quality leads. We have a powerful targeted protein degradation platform called TriNovo. Coupled with a proprietary phenotypic screening platform, our scientists build and rapidly expand a high-quality, differentiated pipeline. Our competitive advantage is a differentiated drug discovery approach, allowing us to advance our pipeline quickly. We continue to drive value through highly validated biology and our differentiated, high-throughput chemistry platform. We focus on execution, rapidly growing our pipeline through corporate and academic alliances. We have worldwide exclusive rights to Rosmantuzumab, anti-RSPO2 mAB, which is a Phase 2 clinical program. We are actively engaged in further pharma partnerships discussion to advance our pipeline programs. We are maximizing Innovo’s expertise, productivity, and efficiency with the Innovo US team’s proven drug discovery experience, leveraging our expertise, and optimizing China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharma company.
